Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations by Michael P. Castro & Neal Goldstein
CASE REPORT Open Access
Mismatch repair deficiency associated with
complete remission to combination
programmed cell death ligand immune
therapy in a patient with sporadic
urothelial carcinoma: immunotheranostic
considerations
Michael P. Castro1* and Neal Goldstein2
Abstract
Background: Mismatch repair deficiency (MMRD) is a common pathway of malignant transformation accounting
for approximately 15–20 % of human carcinogensis. It has been postulated that MMRD increases tumor antigenicity
and highlights a role for immunotherapeutic approach MMR-deficient cancers. This strategy was pursued in a
patient with upper tract urothelial carcinoma, and the results are reported here.
Case Presentation: Molecular profiling was performed using next generation DNA sequencing and (IHC) testing
for MMR and PD-L1. A patient with sporadic, high grade urothelial carcinoma of the renal pelvis was found to have
a hypermutator genotype with 73 mutations occurring amidst 62 known drivers of malignancy, and 340 VUS
alterations. MMR deficiency phenotype was confirmed by the absence of MSH2 and MSH6 as well as deleterious
mutations in these genes. IHC staining for programmed cell death ligand-1 [PD-L1] revealed 2+ staining in 80 % of
cells. The patient gained access to combination immunotherapy trial utilizing MEDI4736 and MEDI0680 through a
clinical trial. The patient achieved a prolonged, complete remission within two months and had no severe ill effects
from the treatment.
Conclusion: Given their ability to generate neo-antigens, MMR-deficient cancers may be uniquely susceptible to
immune checkpoint inhibitor strategies, including urothelial tract cancers. Screening for MMR deficient cancers has
the potential to become a routine strategy for evaluating the role of PD-L1 inhibitors for patient with advanced
disease. (Trial registration: Clinicaltrials.gov NCT00938834. Registered 13 July 2009)
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Background
The integrity of DNA replication depends on intact mis-
match repair [MMR] genes. Patients with epigenetic si-
lencing or deleterious mutations involving these key
enzymes have a predilection for a variety of cancers due
to altered microsatellite nucleotides and replication er-
rors causing a hypermutant phenotype with hundreds or
thousands of mutations. These normally highly con-
served areas of the genome are comprised of repetitive
nucleotide sequences found in both exonic and intronic
DNA. In contrast to chromosomal instability, microsat-
ellite instability (MSI) caused by MMR deficiency repre-
sents a distinct pathway of carcinogenesis through
mutations in genes controlling growth pathways.
The hereditary syndromes involving mutations of mis-
match repair enzymes (MLH1, MSH2, MSH6, and PMS2)
were originally identified by Dr. Henry Lynch and is now
divided into Lynch syndrome I consisting of colon cancer-
only families, and Lynch syndrome II that includes a var-
iety of malignancies such as genitourinary, gynecologic,
and other gastrointestinal cancers [1]. Deleterious muta-
tions in MSH2 are specifically associated with both upper
(5.6 %) and lower tract (12.3 %) urothelial cancers [2].
However not all patients with urothelial carcinoma pos-
sessing MSI have the hereditary syndrome, and somatic
knockout of the MMR genes is possible without any fam-
ily history of cancer: MSI can be identified in approxi-
mately 3 % of bladder cancers and 15 % of sporadic upper
tract urothelial malignancies [3, 4].
Paradoxically, MSI-derived cancers have a better prog-
nosis than microsatellite stable (MSS) cancer in early
stage, but are more poorly responsive to chemotherapy
in the metastatic setting. In colorectal cancer, MSI con-
fers a superior prognosis, adjuvant fluoropyrimidine
therapy produces no benefit and may lead to inferior
survival among patients with stage II disease. But in ad-
vanced colorectal cancer, MSI is frequently associated
with BRAF mutations and portends an unusually poor
prognosis. In urologic cancers as well, MSI indicates a
better prognosis for early stage cancers [5]. On the other
hand, even in germ cell cancer, the most chemotherapy-
responsive solid tumor, MSI is associated with chemo-
therapy resistance [6].
MSI-derived cancer appears to be more antigenic than
MSS malignancies and has a special susceptibility to im-
munotherapeutic strategies. Among patients with MSI-
derived colorectal cancer, the response rate, duration of
response, progression free and overall survival after treat-
ment with an immune checkpoint PD-1 inhibitor, pem-
brolizumab, were vastly superior to the microsatellite
proficient cancers [7]. While this landmark trial contained
a group of patients with non-colorectal cancer, patients
with urothelial cancer were not included in the study.
Thus we present here the complementary experience in a
patient with metastatic, mismatch repair deficient
(MMRD) urothelial carcinoma of the renal pelvis. PD-L1
expression occurs in 45 % of urothelial cancers [8] and
has a 50 % response rate to PD-L1 inhibitor therapy [9].
MEDI4736 is a human IgG1 monoclonal antibody that
binds specifically to PD-L1 and demonstrated durable an-
titumor activity during phase I/II testing [10]. MEDI0680
is a humanized IgG4 mAb that blocks PD-1, thus interfer-
ing with ligand binding of both PD-L1 and PDL-2. This
patient enrolled on a phase I clinical trial testing the com-
bination of MEDI4736 and MEDI0680 [11].
Case presentation
The patient is a 45-year old woman of Japanese descent
with urothelial carcinoma of the right renal pelvis. The
family history was negative for any malignancies in first-
degree relatives. She has been a life-long non-smoker and
has no occupational exposure to aniline dyes, radiation, or
other chemicals. After presenting with gross hematuria in
November 2013, a CT-IVP showed an abnormal, mass-
like infiltration measuring 2.9 x 2.4 x 3 cm of the middle
to lower right renal collecting system involving the renal
parenchyma and invading the sinus fat. Ureteroscopy and
biopsy revealed a transitional cell malignancy of the right
lower pole renal calyx. In December 2013, she underwent
a hand-assisted right nephroureterectomy.
Pathology revealed high-grade urothelial carcinoma in-
vading the renal parenchyma and peripelvic fat without a
significant inflammatory component (Fig. 1). The resec-
tion margins were negative. She was deemed as having G3
pT3N0M0, AJCC Stage III cancer. Post-operatively, she
received 6 cycles of adjuvant gemcitabine-cisplatin chemo-
therapy and completed the treatment by July 2014. A CT
scan immediately following adjuvant treatment revealed a
new contralateral lymphadenopathy measuring 1.2 cm.
Subsequently, a repeat scan revealed a new nodular lesion
in the right renal bed and an increase in the dimensions of
Fig. 1 H&E high power showing high-grade urothelial carcinoma
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the left sided lymph node to 2.3 cm including two add-
itional areas of metastatic disease: a lesion overlying the
right iliopsoas muscle and the left para-aortic adenopathy.
PET scanning disclosed that the 3 lesions seen on CT were
hypermetabolic. A CT-guided biopsy confirmed metastatic
urothelial carcinoma.
Molecular profiling was performed at Foundation
Medicine, Inc. utilizing next generation DNA sequen-
cing to identify actionable genomic alterations in key on-
cogenes and tumor suppressor genes [exonic regions of
315 genes]. This testing revealed 73 mutations among 62
genes (Table 1). Additionally, 340 variants of unknown
significance [VUS] abnormalities were also identified
among 166 genes (not shown). Three deleterious muta-
tions were identified in MSH2 (A913fs*2, E226*, E580*)
and one in MSH6 (R361H) (Table 1).
The hypermutant genotype was phenotypically evalu-
ated with 4-gene MMR IHC testing that showed loss of
expression of both MSH2 and MSH6 (Table 2).
Germline DNA testing at Myriad Inc. was negative for
all known Lynch mutations. Subsequently, the patient’s
primary tumor was tested at Clarient GE, Inc. [Aliso
Viejo, CA] for PD-L1 expression and found 2+ staining
in 80 % of cells (Fig. 2).
The patient enrolled on a phase I clinical trial of an anti-
PD-L1 inhibitor MEDI4736 and MEDI0680, [MedImmune
Inc., Gaithersburg, MD] in Los Angeles [Clinical trial #:
NCT02118337]. Within 2 months at the first radiographic
evaluation, she had a complete disappearance of all cancer
(Fig. 3). After 10 months of treatment, she developed grade
1–2 uritcarial rash and polyarthralgias in her hands and a
positive ANA 1:160, but has no signs of severe or life-
threatening autoimmunity or other criteria for a diagnosis
of SLE. She has a confirmed continuous complete remis-
sion at 11 months and continues to participate on study.
Conclusions
This patient had progressive, metastatic disease at the
conclusion of platinum-based adjuvant therapy exempli-
fying the phenomenon of chemotherapy resistance and
treatment failure characteristic of MMRD cancer. Des-
pite the MSI phenotype, her primary cancer did not have
a brisk tumor infiltrating lymphocyte (TIL) population.
In retrospect, this observation is consistent with anergy
caused by a strongly PD-L1 expressing cancer, and
hinted at her inevitable relapse rather than the favorable
outcome usually associated with MSI-derived cancers.
At relapse, the molecular profiling evaluation revealed a
hypermutant genotype and led to discovering the som-
atic knockout of MSH2 and MSH6 induced by deleteri-
ous mutations. While this patient’s cancer proved to
have deleterious mutations in MSH2 and MSH6, IHC
Table 1 Molecular profiling results from FoundationOne™ testing. 73 deleterious mutations were identified among 62 genes known
drivers of cancer. Additional 340 variants of unknown significance [VUS] abnormalities were identified among 166 genes (not
shown). Four mutations were identified in mismatch repair genes MSH2 and MSH6
ERBB4 R842Q TP53 P222L, R175C, R282W MSH6 R361H
FBXW7 R689Q APC R856C MSH2 A913fs*2,E580* E226*
FGFR3 R248C AR R616H
JAK2 D319N ARID1A R1989* MYST3 R79Q
KRAS A18T ARID2 L390fs*1, Q819*, R1677* NOTCH2 R2036*
NF2 R424C ATRX R2131, 6849 + 2 T > C POLE V411L
PTCH1 R135* CHEK2 W97* PRDM1 A5O2T
ROS1 A114OT CIC R1515H PREX2 R1149H
TET2 E149* CTCF R11W SLIT2 C1022*, R942*,2417+ 2 T>C
ATM R1875* CUL3 R148*
ATR R1082H EPHB1 G642D SMAD4 R361H
CDKN2A p16INK4a, A68T, p14ARF l FAT1 S4314fsa6 SMARCA4 R1093a
CHEK1 R160H FLT3 485-1G > A SPEN R2081a
CREBBP R2344W GRIN2A E1461K, R1206a SPTA1 R374Q
EP300 R838C HNF1A S574N TAF1 R1172a
FANCA T1161M KDM6A R1279a TGFBR2 R528C
NTRK1 R649W MLL2 R4238C, R4904a WT1 T358M
Table 2 Mismatch repair IHC testing results
GENE Antibody Result
MLH1 G168-15 Normal expression
PMS2 A16-4 Normal expression.
MSH6 BC/44 Loss of expression.
MSH2 FE11 Loss of expression.
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testing for MSI to identify epigenetic silencing in the ab-
sence of mutation represents an exceptional example
where NGS assessments of DNA cannot substitute for
protein assessment.
Given the impracticality of inhibiting dozens of de-
ranged driver pathways in this patient’s disease with any
targeted or conventional cytotoxic strategy, the identifica-
tion of MMRD and PD-L1 over-expression provided a
plausible hypothesis for controlling her metastatic cancer,
even though neither biomarker was required for partici-
pating on this clinical trial. Indeed, had those tests been
negative, it would not have excluded an immunologic
strategy. On the other hand, the identification of PD-L1
expression created enthusiasm for accessing checkpoint
inhibitor therapy. The clinical trial she enrolled on is ac-
tively testing the combination of MEDI4736 mAb that
blocks PD-L1 and MEDI0680 mAb that blocks PD-1, a
dual blockade that may be more effective than targeting
either target alone [12]. The results of this accruing trial
are eagerly awaited.
To our knowledge, this is the first documented case of
specifically characterized MMRD-urothelial cancer with
a clinical benefit from PD-L1 immunotherapy. The sig-
nificance of the observation derives from the universal
experience of treating metastatic urothelial cancer where
patients with platinum-refractory disease seldom have
meaningful, durable responses to subsequent chemo-
therapy and usually survive no longer than a matter of
months. Other PD-L1/PD-1 agents, MPDL3280A, atezo-
lizumab, and MK3475, pembrolizumab, have already
been reported as having impressive efficacy in urothelial
cancer, but so far there has been no evaluation whether
those patients’ cancers had MMRD [8, 13]. This case re-
port begs the question of MMRD status in these studies
to see if the association holds in a larger cohort.
Whole exome sequencing (WES) has demonstrated
that mutation load has a direct bearing on a given can-
cer’s immunogenicity and predicts the likelihood of
benefit from ipilumumab [14]. It follows that the MSI
phenomenon which causes 10 to 1000 times more muta-
tions than found in MSS cancers creates neo-antigens
and increases antigenicity, thus explaining the usual in-
flammatory reaction of TIL, and accounting for the im-
proved prognosis of early stage, MMRD cancers. At the
same time, PD-L1 expression has emerged as one of the
fundamental escape mechanisms by which malignant
diseases bypass immunosurveillance resulting in meta-
static progression and adaptive immune resistance
[15, 16]. As such, PD-L1 testing in the primary tumor
could emerge as a prognostic biomarker for relapse as
well as a promising strategy for selecting patients
most likely to benefit from adjuvant checkpoint inhib-
ition. It is also noteworthy that while the NGS ana-
lysis in this report contained only 315 genes, the
131 % frequency of genetic alterations suggests that
more limited assays may be able to substitute for
WES for determining elevated mutation load as a bio-
marker for immunotherapy in the future.
MMRD has been identified as a predictive biomarker
for PD-1 immunotherapy in patients with colorectal
Fig. 3 The baseline film in November reveals a necrotic lymph node in the left para-aortic region adjacent to the ureter. The follow-up study in
March 2015 shows a complete disappearance of the lesion
Fig. 2 Strongly positive PD-L1 immunostaining (Clarient GE, Inc.)
Sections were cut and dewaxed followed by application of the
primary PD-L1 antibody (Cell Signaling Co., clone E1L3N, 1:150) and
PD-1 antibody (CellMarque Co., clone MRQ-22, 1:300). After washes,
DAB was used as the chromogen and slides were counterstained
with hematoxylin
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cancer leading to unsurpassed response rates, 90 % dis-
ease control, and prolonged survival. The results in
other non-colorectal, MSI-derived cancers are just as
impressive in that study [7]. At the same time, MSI may
represent only one of a variety of pathways for generat-
ing increased mutation load, enhancing antigenicity, and
creating a high chance for benefit from immunotherapy.
The susceptibility of heavy carcinogen-associated can-
cers, such as lung and head and neck cancers, to check-
point immunotherapy supports the notion that the
antigenicity of cancer increases with rising mutation
burden from any cause. Emerging data in hepatoma and
head and neck cancer also suggests that malignancies
caused by viral infections capable of altering normal cel-
lular antigen expression, including HBV, HCV, EBV, and
HPV might also be uniquely responsive to immune
checkpoint inhibitors [17, 18].
At the present time, the optimal biomarker approach for
identifying benefit from immune checkpoint-directed ther-
apy remains an open and complex issue. The clinical role
of PD-L1 biomarker testing while not quite “investigational”
is still in a formative stage. Already, it has been demon-
strated that PD-L1/PD-1 IHC staining intensity is corre-
lated with the likelihood and duration of benefit in lung
cancer. On the other hand, the absence of staining does not
preclude the possibility that immune checkpoint inhibition
will lead to disease control [19, 20]. The ideal antibody has
not been identified, such that the commercially available
PD-L1 antibodies have specificity for different epitopes and
can yield discordant results from the same tissue [21]. Add-
itionally, discordant expression between a primary tumor
and its metastases as well as heterogenous staining, ranging
from 0 to 3+ within a given tissue sample, argue for a
skeptical interpretation of any negative IHC result. Quanti-
tative PCR testing of PD-L1 appears promising [22], but so
far has not been prospectively evaluated against IHC tech-
niques. Finally, PD-L1 staining by itself is no guarantee
that targeting this mechanism will control the disease.
Other mechanisms modulate the immune response, in-
cluding IDO-1, PD-L2 and LAG-3, and represent add-
itional potential biomarkers of resistance [23]. Even a
desmoplasic tumor microenvironment arising from ex-
pression of fibroblast activated proteins that impede T
cells from gaining access to cancer cells appears to facili-
tate immune tolerance, and could represent a marker of
resistance as well as another mechanism for drug develop-
ment to overcome [24]. On the other hand, the absolute
lymphocyte count and its incremental changes during
treatment appear to be robust predictors of survival benefit
among melanoma patients treated with ipilumumab [25].
Despite the daunting complexity that emerges from these
discoveries, they offer hope that assay-directed, rational tar-
geting of key mechanisms of immune evasion, i.e. “preci-
sion immunology,” will become feasible and direct the
optimal combination strategies to overcome resistant dis-
ease for individual patients. At the moment, both MMRD
and PD-L1 appear to have merits as biomarkers for PD-L1/
PD-1 antibodies with regard to using a one-sided predictive
rule, making immunotherapy a priority whenever either
one or both are present. Also promising, ICOS [26] and
NY-ESO-1 [27, 28] represent candidate markers for predict-
ing response to CTLA-4 antibodies. The 58–60 % decrease
in disease progression associated with combination im-
mune checkpoint inhibitor therapy for untreated melanoma
creates a high priority for identifying which patients need
the combination and its attendant risks, and which can
benefit from PD-L1 therapy alone and spared unnecessary
cost and toxicity [29, 30].
While the new biomarker science of immunodiagnostics
matures, an increased and broadly applied index of suspi-
cion for detecting MMRD among the entire spectrum of
malignant disease [especially GI, GU, and GYN cancer]
appears warranted and has important immunotheranostic
implications. Drug development targeting either MMRD
or PD-L1 irrespective of tumor site of origin could well
turn out to be an effective strategy for advancing patient
outcomes compared to conventional, disease site-limited
trial design and the cytotoxic options that perform poorly
in MMRD cancers. With appropriate regulatory support,
the success of such trials promises to define a new para-
digm in the treatment of human cancer.
Trial registration
Clinicaltrials.gov NCT00938834. Registered 13 July 2009.
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